Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q3 2026 · 10-Q
Revenue$0.00$0.00— vs Q3 2025 Net Income-$11.94M-$11.94MN/M vs Q3 2025 EPS Diluted-$0.24-$0.24N/M vs Q3 2025 Operating Income-$13,582,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,467,000N/M ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end